Forgot Password?
Return to Course Listing

CME: Best practices in the real-world clinical management of malignant mesothelioma


Activity Description / Statement of Need:

In this online, self-learning activity:

Malignant mesothelioma (MM) is a relatively rare, aggressive cancer that most commonly affects the pleural space (81%) in cases of malignant pleural mesothelioma (MPM), followed by the peritoneum (9%). Over 80% of MPM patients and 33% of patients with peritoneal MM have a documented prior exposure to asbestos or related minerals. It is thought that the inhaled asbestos fibers interact with mesothelial and inflammatory cells, leading to repeatedly prolonged cell cycles and direct DNA damage. There are three distinct histologic subtypes of MPM, but determining subtypes requires expert assessment and suitable biopsies that are not always available, which may lead to delays in the start of treatment.

Target Audience:

HCPs including: Medical oncologists and pulmonologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with malignant mesothelioma.

Commercial Support Disclosure: This program is supported by an educational grant from Novocure.

This activity is free of charge.

Release Date: May 04, 2023 -- Expiration Date: May 04, 2024

Faculty: Jae Y. Kim, MD


Introduction, faculty disclosures

Epidemiology, risk factors, and different types of malignant mesothelioma

· Incidence, histology, pathophysiology, and prognosis of mesothelioma

· Risk factors, including asbestos exposure, race, age, gender

· Types of malignant mesothelioma

· Complications and burden associated with malignant mesothelioma

Diagnosis and treatment of malignant mesothelioma

· Guideline-recommended and data-supported updates in the diagnosis and treatment of mesothelioma

· Diagnostic delays, limitations of current diagnostic tools, with an emphasis on imaging techniques and biopsies

·  Present standards of care in the treatment of mesothelioma and limitations, including outcomes

o   Epitheloid vs. nonepitheloid histology

o   PD-1/PD-L1- and CTLA-4-targeting therapy

o   Antifolate plus platinum compound

o   VEGF-targeting

o   Tumor-treating fields

· Emerging investigational therapies: other immune checkpoint inhibitors and targeted therapies

· Patient cases

Summary, conclusion, and best practice gaps

Learning Objectives

By the end of the session the participant will be able to:

  • Describe challenges in the identification and treatment of malignant mesothelioma
  • Identify present and emerging diagnostic and treatment options for malignant mesothelioma
  • Formulate a treatment plan for a patient with malignant mesothelioma


ACCME Activity #202515755


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Jae Y. Kim, MD, Chief, Division of Thoracic Surgery, City of Hope National Medical Centerhas received financial compensation from Astra-Zeneca, Eli Lilly and Intuitive for consulting and/or research and/or speaker's bureau work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Novocure.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

Myeloma bone disease: Monitoring and management

Addressing unmet needs and updates in the pharmacotherapeutic management of alpha-1 antitrypsin deficiency (AATD) and its complications

Optimizing care in advanced non-small cell lung cancer (NSCLC): Zeroing in on personalized medicine with precision